Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, Raynal NJ.

J Exp Clin Cancer Res. 2019 Jun 13;38(1):251. doi: 10.1186/s13046-019-1242-8.

2.

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ.

Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25.

PMID:
30454645
3.

DNA Methylation-Targeted Drugs.

Da Costa EM, McInnes G, Beaudry A, Raynal NJ.

Cancer J. 2017 Sep/Oct;23(5):270-276. doi: 10.1097/PPO.0000000000000278. Review.

PMID:
28926427
4.

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.

Mol Cancer Ther. 2017 Feb;16(2):397-407. doi: 10.1158/1535-7163.MCT-16-0588. Epub 2016 Dec 15.

5.

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.

Malouf GG, Su X, Zhang J, Creighton CJ, Ho TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, Mouawad R, Spano JP, Khayat D, Wood CG, Jelinek J, Tannir NM.

Clin Cancer Res. 2016 Dec 15;22(24):6236-6246. Epub 2016 Jun 2.

6.

Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.

Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP.

Cancer Res. 2016 Mar 15;76(6):1494-505. doi: 10.1158/0008-5472.CAN-14-2391. Epub 2015 Dec 30.

7.

Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.

Yamazaki J, Taby R, Jelinek J, Raynal NJ, Cesaroni M, Pierce SA, Kornblau SM, Bueso-Ramos CE, Ravandi F, Kantarjian HM, Issa JP.

J Natl Cancer Inst. 2015 Nov 13;108(2). pii: djv323. doi: 10.1093/jnci/djv323.

8.

Epigenetic synergy between decitabine and platinum derivatives.

Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JJ.

Clin Epigenetics. 2015 Sep 11;7:97. doi: 10.1186/s13148-015-0131-z. eCollection 2015.

9.

Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Malouf GG, Tahara T, Paradis V, Fabre M, Guettier C, Yamazaki J, Long H, Lu Y, Raynal NJ, Jelinek J, Mouawad R, Khayat D, Brugières L, Raymond E, Issa JP.

Epigenetics. 2015;10(9):872-81. doi: 10.1080/15592294.2015.1076955.

10.

Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition.

Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, Mani SA, Issa JP.

Genome Biol. 2013 Dec 24;14(12):R144. doi: 10.1186/gb-2013-14-12-r144.

11.

DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.

Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP.

Cancer Res. 2012 Mar 1;72(5):1170-81. doi: 10.1158/0008-5472.CAN-11-3248. Epub 2012 Jan 4.

12.

Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees.

Spannhoff A, Kim YK, Raynal NJ, Gharibyan V, Su MB, Zhou YY, Li J, Castellano S, Sbardella G, Issa JP, Bedford MT.

EMBO Rep. 2011 Mar;12(3):238-43. doi: 10.1038/embor.2011.9. Epub 2011 Feb 18.

13.

3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.

Raynal NJ, Momparler LF, Rivard GE, Momparler RL.

Leuk Res. 2011 Jan;35(1):110-8. doi: 10.1016/j.leukres.2010.04.014. Epub 2010 May 26.

PMID:
20510451
14.

Synergistic effect of 5-Aza-2'-deoxycytidine and genistein in combination against leukemia.

Raynal NJ, Charbonneau M, Momparler LF, Momparler RL.

Oncol Res. 2008;17(5):223-30.

PMID:
18980019
15.

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL.

BMC Cancer. 2008 May 2;8:128. doi: 10.1186/1471-2407-8-128.

16.

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.

Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL.

Cancer Chemother Pharmacol. 2009 Feb;63(3):411-6. doi: 10.1007/s00280-008-0750-6. Epub 2008 Apr 9.

PMID:
18398609
17.

Antileukemic activity of genistein, a major isoflavone present in soy products.

Raynal NJ, Momparler L, Charbonneau M, Momparler RL.

J Nat Prod. 2008 Jan;71(1):3-7. doi: 10.1021/np070230s. Epub 2007 Dec 29.

PMID:
18163589
18.

Cadmium uptake in isolated adrenocortical cells of rainbow trout and yellow perch.

Raynal NJ, Hontela A, Jumarie C.

Comp Biochem Physiol C Toxicol Pharmacol. 2005 Mar-Apr;140(3-4):374-82.

PMID:
15914089

Supplemental Content

Loading ...
Support Center